E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonsteroidal antiinflammatory drug (NSAID) intolerance. The prevalence of AERD remains unclear. It is estimated that among patients with CRSwNP approximately 30% have allergic asthma and 15% have aspirin intolerance. |
|
E.1.1.1 | Medical condition in easily understood language |
Triad of allergic asthma, nasal polyps and intolerance to pain killers (aspirin) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To test the efficacy of dupilumab in 30 patients with AERD regarding the intolerance to salicylic acid after 6 months. This will be evaluated by oral drug provocation testing with low dose salicylic acid after 6 months of dupilumab treatment. As control groups 10 patients with polyps without aspirin intolerance and 10 healthy controls will undergo apirin provocation testing. |
|
E.2.2 | Secondary objectives of the trial |
Serum ECP, total IgE, allergen-specific IgE, tryptase, peripheral blood eosinophils Skin prick test Smell identification test (UPSIT) for assessment of olfaction Cytokine pattern in nasal secretions at indicated timepoints and also before and after provocation Nasal mucosa as assessed by nasal biopsies before and after one month of therapy Inflammatory cytokine patterns at mRNA levels in samples obtained by nasal curettes Nasal microbiome Total nasal endoscopic polyps scores (TPS), Sino-Nasal Outcome Test-22 (SNOT-22), which measures the quality of life of patients with chronic rhinosinusitis 3-5 Sinus computed tomographic scans (Lund-McKay) Asthma control test (ACT), Asthma control questionnaire (ACQ) Lung function Baseline, concomitant medication (CM) at all time points |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age 18 – 70 • Female and male patients • Diagnosed with AERD (nasal polyps, asthma, aspirin intolerance) o CRwNP (according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines)8 o Documented aspirin intolerance o Allergic asthma bronchiales diagnosed by a respiratory physician (based on Global Initiative for Asthma guidelines) Signed and dated informed consent form |
|
E.4 | Principal exclusion criteria |
• Pregnancy • Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A/B/C) • History of malignancy or immunodeficiency • Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis) • Need for systemic corticosteroid therapy 1 month prior to screening visit |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effect regarding the tolerance to salicylic acid of patients with AERD following dupilumab therapy for 6 months. After 6 months of therapy, patients will not tolerate aspirin dose levels as tested with different dosages (125mg, 250mg and 500 mg) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Changes in blood- or nasal–derived biomarkers, total nasal endoscopic polyps scores, patients' quality of life or allergic asthma |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |